Edwards Lifesciences (EW) Receivables - Other (2009 - 2026)

Edwards Lifesciences' Receivables - Other history runs 18 years deep, the most recent figure standing at $197.3 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 138.57% year-over-year to $197.3 million; the TTM figure through Mar 2026 stood at $197.3 million (up 138.57% YoY), while the FY2025 annual figure was $252.5 million, up 113.44% from the prior year.
• Receivables - Other was $197.3 million for Q1 2026 at Edwards Lifesciences, down from $252.5 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $252.5 million in Q4 2025 to a low of $42.8 million in Q2 2022.
• Historically, Receivables - Other has averaged $100.1 million across 5 years, with a median of $62.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Receivables - Other plunged 35.78% in 2022, then surged 266.49% in 2025.
• A 5-year view of Receivables - Other shows it stood at $56.1 million in 2022, then climbed by 0.89% to $56.6 million in 2023, then jumped by 109.01% to $118.3 million in 2024, then soared by 113.44% to $252.5 million in 2025, then retreated by 21.86% to $197.3 million in 2026.
• The last three Receivables - Other figures came in at $197.3 million (Q1 2026), $252.5 million (Q4 2025), and $199.5 million (Q3 2025), per Business Quant data.